Literature DB >> 16526059

Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells.

Irina Mantovani1, Alessandra Cappellini, Pier Luigi Tazzari, Veronica Papa, Lucio Cocco, Alberto M Martelli.   

Abstract

Multidrug resistance (MDR) mediated by the drug efflux protein, 170-kDa P-glycoprotein (P-gp), is one mechanism that tumor cells use to escape cell death induced by chemotherapeutic drugs. Moreover, evidence suggests that cell lines expressing high levels of 170-kDa P-gp are less sensitive to caspase-mediated apoptosis induced by a wide range of death stimuli, including Fas ligand, tumor necrosis factor, and ultraviolet irradiation. However, the fate of 170-kDa P-gp during apoptosis is unknown. In this study, we demonstrate for the first time that 170-kDa P-gp is cleaved during apoptosis of VBL100 human T-lymphoblastoid CEM cells. Apoptotic cell death was induced by LY294002 (a pharmacological inhibitor of the phosphoinositide 3-kinase/Akt survival pathway), H2O2, and Z-LEHD-FMK (a caspase-9 inhibitor which has been recently reported to induce apoptosis in CEM cells). Using an antibody to a common epitope present in both the third and the sixth extracellular loop of P-gp, two cleavage products were detected, with an apparent molecular weight of 80 and 85 kDa. DEVD-FMK (a caspase-3 inhibitor), but not VEID-CHO (a caspase-6 inhibitor), blocked 170-kDa P-gp cleavage. Recombinant caspase-3 was able to cleave in vitro 170-kDa P-gp yielding two fragments of equal size to those generated in vivo. Considering the size of the cleaved fragments and their reactivity with antibodies, which recognize either the N-half or the C-half region of the protein, it is conceivable that the cleavage occurs intracytoplasmically. Since 170-kDa P-gp has been reported to counteract apoptosis, its cleavage may be a mechanism aimed at blocking an important cell survival component. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16526059     DOI: 10.1002/jcp.20628

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  13 in total

1.  Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.

Authors:  Xia Xue; Xian-Jun Qu; Zu-Hua Gao; Cui-Cui Sun; Hui-Ping Liu; Cui-Rong Zhao; Yan-Na Cheng; Hong-Xiang Lou
Journal:  Invest New Drugs       Date:  2010-10-06       Impact factor: 3.850

2.  Mitochondrial expression and activity of P-glycoprotein under oxidative stress in outer blood-retinal barrier.

Authors:  Yue-Hong Zhang; Juan Li; Wei-Zhong Yang; Zhuan-Hua Xian; Qi-Ting Feng; Xiang-Cai Ruan
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

Review 3.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

4.  siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.

Authors:  Dae Won Kim; Kyung-Ok Kim; Mike J Shin; Jung Hee Ha; Sung Wook Seo; Jay Yang; Francis Y Lee
Journal:  Mol Cancer       Date:  2009-05-15       Impact factor: 27.401

5.  TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases.

Authors:  Suk-Bin Seo; Jung-Gu Hur; Mi-Ju Kim; Jae-Won Lee; Hak-Bong Kim; Jae-Ho Bae; Dong-Wan Kim; Chi-Dug Kang; Sun-Hee Kim
Journal:  Mol Cancer       Date:  2010-07-28       Impact factor: 27.401

6.  Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.

Authors:  Federica Falà; William L Blalock; Pier Luigi Tazzari; Alessandra Cappellini; Francesca Chiarini; Giovanni Martinelli; Agostino Tafuri; James A McCubrey; Lucio Cocco; Alberto M Martelli
Journal:  Mol Pharmacol       Date:  2008-06-24       Impact factor: 4.436

7.  MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.

Authors:  Lirong Ren; Lan Xiao; Jianli Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12

8.  The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers.

Authors:  Alessandra Cappellini; Francesca Chiarini; Andrea Ognibene; James A McCubrey; Alberto M Martelli
Journal:  Cell Cycle       Date:  2009-05-02       Impact factor: 4.534

9.  Mitochondrial localization of P-glycoprotein and peptide transporters in corneal epithelial cells--novel strategies for intracellular drug targeting.

Authors:  Megha Barot; Mitan R Gokulgandhi; Dhananjay Pal; Ashim K Mitra
Journal:  Exp Eye Res       Date:  2012-10-29       Impact factor: 3.467

10.  Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells.

Authors:  Xianlong Ling; Yuan Zhou; Shi-Wei Li; Bin Yan; Lei Wen
Journal:  Int J Biol Sci       Date:  2010-12-06       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.